Unusual flexural drug reaction with epidermal pustules associated with adalimumab treatment.

The use of tumor necrosis factor-alpha (TNF-alpha) inhibitors in the management of chronic inflammatory conditions is increasing in dermatology and rheumatology practices. We report a case of an unusual drug eruption in flexural areas occurring in a patient treated with adalimumab for rheumatoid arthritis. A fifty-one-year old woman with a fourteen-month history of seropositive rheumatoid arthritis presented for evaluation of an erythematous, pruritic rash in flexural areas. The eruption began four months after initiating adalimumab, a TNF-alpha inhibitor for her rheumatoid arthritis. Adalimumab was temporarily discontinued for four weeks with improvement of the cutaneous eruption; however, the eruption reappeared three weeks after the medication was reinitiated and had an identical appearance. Drug regimen review revealed no other recent medication adjustments. The patient did not have a personal or family history of psoriasis. Concurrent medications included aspirin, hydrochlorothiazide, hydroxychloroquine, and metformin. Rheumatoid factor, ESR-Westergreen, and C-reactive protein levels were elevated at 825 IU/ml, 72mm/h and 3.63 mg/dl, respectively. ESR and C-reactive protein were within normal limits 4 months prior to the eruption. Physical examination after adalimumab re-challenge revealed red-brown plaques with slightly mammilated/pebbly surface involving both axillae and smaller plaques in the left antecubital fossa and on the left wrist (Fig 1). There were no other skin or nail findings or oral lesions. A punch biopsy showed epidermal hyperplasia and spongiosis, with multiple foci of neutrophils and eosinophils within variably sized intraepidermal pustules (Figs 2a and b). The papillary dermis also contained numerous neutrophils and eosinophils. Sterile biopsy did not grow bacteria, fungi or mycobacteria. The diagnosis of pustular drug eruption was made. Figure 1 Red-brown plaques in axillae after rechallenge with adalimumab Figure 2 Figure 2a. Routine histology showing acanthotic epidermis with intraepidermal pustule (10x) Adalimumab, a recombinant human IgG1 monoclonal antibody specific for TNF-alpha, is administered via subcutaneous injection every two weeks for rheumatoid arthritis. The most common side effect is a local injection site reaction. This was seen in 20.9% of patients treated with adalimumab compared to 13.8% treated with placebo in an analysis of four clinical trials.1 Other adalimumab associated skin reactions are rare and include leukocytoclastic vasculitis,2urticaria 3, eczema 4 and a pustular eruption involving the palms and soles.5 There are increased numbers of patients with rheumatological conditions treated with TNF-alpha inhibitor that develop new onset or worsening psoriasis, often with prominent palmoplantar involvement.6+7 5 Table 1 summarizes some cutaneous reactions reported with TNF-alpha inhibitors. Table I Adverse cutaneous reactions with recombinant TNF-alpha inhibitors 1–7 We favor adalimumab as a causative agent in this pustular eruption due to the temporal nature of the adalimumab initiation and onset of cutaneous lesions. The rapid improvement of the eruption with discontinuation and flare with re-challenge further support our theory. Biopsy showing numerous eosinophils, commonly seen in drug eruptions, is also consistent with an adalimumab-induced pustular eruption. Cutaneous pustular adverse events have been reported in patients treated with infliximab, adalimumab, and etanercept, . The mechanism for these eruptions is not known, but it has been postulated that TNF-alpha and interferon cross regulation play an important role in pathogenesis. 7. Our case is unusual in that it involves flexural areas and has eosinophilic pustules in the epidermis. In conclusion, physicians monitoring patients utilizing antibody-type TNF-alpha inhibitors must recognize the potential for induction of pustular dermatoses.